“`html
wegovy Set for Australian PBS Listing, Balancing Equity and Fiscal concerns
A new weight loss medication, Wegovy, is poised to be listed on Australia’s Pharmaceutical Benefits Scheme (PBS), offering considerable savings to patients with severe obesity and cardiovascular disease – but at a perhaps significant cost to taxpayers.
The Australian government, under health Minister Mark Butler, has committed to subsidizing Wegovy for individuals with an “established cardiovascular disease,” such as those who have experienced a heart attack or stroke, and a Body Mass Index (BMI) of 35 or higher. This decision follows a recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) late last year.
understanding Wegovy and GLP-1 Medications
Wegovy is a glucagon-like peptide-1 (GLP-1) medication, functioning similarly to Ozempic. These medications work by suppressing appetite, leading to weight loss. Currently, Ozempic is only available on the PBS for patients with type 2 diabetes, the condition for which GLP-1 medications were originally developed. However, the World Health Organization (WHO) recently endorsed these medications as long-term treatments for obesity, urging governments worldwide to improve affordability and access.
Addressing a Critical health and Equity Issue
According to Minister butler, the move is driven by both health and equity concerns. “Right now, more than 400,000 Australians are paying market prices for one of the GLP-1s, and that is as much as $4,000 or $5,000 a year, which is obviously beyond the means of many Australians,” he stated on friday.Data from 2022 indicates that 13% of Australian adults fall into the category of “severe obesity,” defined as having a BMI of 35 or greater.
The PBS listing promises to dramatically reduce the cost for eligible patients.Recent changes to the PBS have already lowered medication costs to $25 per script and $7.70 for concession card holders.
Fiscal Concerns and Cost Management
Despite the potential benefits, the government acknowledges the financial implications. Minister Butler warned of a “very big bill for taxpayers” associated with subsidizing Wegovy. His office declined to provide a specific cost estimate, stating that a clearer picture will emerge during price negotiations with manufacturer Novo nordisk.
The PBAC, in its December advice, highlighted a “significant risk” that individuals not meeting the strict criteria – particularly those meeting only one threshold – would attempt to access the subsidized medication. To mitigate this, a “risk sharing arrangement” with Novo Nordisk will be necessary to manage government costs.
Narrow Criteria to Control costs
Mark Mellor, lead clinician at Perth Weight Clinic, explained that the eligibility criteria were “deliberately narrow” to prevent a cost escalation. He emphasized the significant benefits of the drug for the targeted population, noting that it not only addresses weight loss but also helps prevent future cardiovascular events and potentially saves lives. “to help prevent them from having another cardiovascular event or dying from cardiovascular disease,” Dr. Mellor said, “it makes sense that we need to treat these people if they want that treatment.”
Potential Risks Under Scrutiny
While the WHO has championed GL
